改良乘数SES-CD预测克罗恩病内镜缓解
本研究基于三项克罗恩病临床试验的事后分析(n=350,基线SES-CD≥3且确认溃疡),将数据随机分为70%训练集和30%测试集,开发并验证改良乘数SES-CD(MM-SES-CD)以预测1年内镜缓解(SES-CD<3)。MM-SES-CD在训练集和测试集中均显示出较强的判别能力(AUC分别为0.83和0.82),而原始SES-CD预测准确性较低(AUC 0.60)。
要点
- MM-SES-CD通过加权溃疡大小、范围和狭窄等参数预测1年内镜缓解。
- MM-SES-CD在训练集和测试集中AUC分别为0.83和0.82,判别力强。
- 原始SES-CD预测内镜缓解的AUC仅为0.60,准确性不足。
核心结论
- MM-SES-CD可作为内镜严重度评估工具,预测接受积极治疗的克罗恩病患者1年内镜缓解。
研究设计与样本
- 对三项克罗恩病临床试验进行事后分析,共纳入350例基线SES-CD≥3且确认溃疡的患者,数据随机分为70%训练集和30%测试集。
主要发现
- 基线溃疡大小、溃疡范围和存在不可通过的狭窄与1年内镜缓解关联最强。
- MM-SES-CD在训练集中预测内镜缓解的AUC为0.83(95%CI 0.78-0.94),在测试集中为0.82(95%CI 0.77-0.92)。
- 原始SES-CD预测内镜缓解的AUC为0.60(95%CI 0.55-0.65),准确性较低。
关键数值与推荐
- 1年内镜缓解定义为SES-CD<3。
- MM-SES-CD通过逻辑回归模型对每个参数加权生成,低概率和高概率内镜缓解的切点由最大约登指数确定并在测试集中验证。
临床怎么用
- 在临床实践中,可使用MM-SES-CD评估克罗恩病患者接受积极治疗时1年内镜缓解的概率,辅助治疗决策。
局限性
- 本研究为事后分析,样本来自临床试验人群,需外部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: The Simple Endoscopic Score for Crohn's disease (SES-CD) is the primary tool for measurement of mucosal inflammation in clinical trials but lacks prognostic potential. We set to develop and validate a modified multiplier of the SES-CD (MM-SES-CD), which takes into consideration each individual parameter's prognostic value for achieving endoscopic remission (ER) while on active therapy. METHODS: In this posthoc analysis of three CD clinical trial programmes (n=350 patients, baseline SES-CD ≥ 3 with confirmed ulceration), data were pooled and randomly split into a 70% training and 30% testing cohort. The MM-SES-CD was designed using weights for individual parameters as determined by logistic regression modelling, with 1-year ER (SES-CD < 3) being the dependent variable. A cut point score for low and high probability of ER was determined by using the maximum Youden Index and validated in the testing cohort. RESULTS: Baseline ulcer size, extent of ulceration and presence of non-passable strictures had the strongest association with 1-year ER as compared with affected surface area, with differential weighting of individual parameters across disease segments being observed during logistic regression. The MM-SES-CD was generated using this weighted regression model and demonstrated strong discrimination for ER in the training dataset (area under the receiver operator curve (AUC) 0.83, 95% CI 0.78 to 0.94) and in the testing dataset (AUC 0.82, 95% CI 0.77 to 0.92). In comparison to the MM-SES-CD scoring model, the original SES-CD score lacks accuracy (AUC 0.60, 95% CI 0.55 to 0.65) for predicting the achievement of ER. CONCLUSIONS: We developed and internally validated the MM-SES-CD as an endoscopic severity assessment tool to predict one-year ER in patients with CD on active therapy.
引用
- Narula N, Wong ECL, Colombel JF, et al. Predicting endoscopic remission in Crohn's disease by the modified multiplier SES-CD (MM-SES-CD). Gut. 2021. PMID: 33766910. doi:10.1136/gutjnl-2020-323799
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。